These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 25829273)

  • 1. The breast cancer market.
    Syed BA
    Nat Rev Drug Discov; 2015 Apr; 14(4):233-4. PubMed ID: 25829273
    [No Abstract]   [Full Text] [Related]  

  • 2. The breast cancer drug market.
    Wilcock P; Webster RM
    Nat Rev Drug Discov; 2021 May; 20(5):339-340. PubMed ID: 33483705
    [No Abstract]   [Full Text] [Related]  

  • 3. Market watch: Upcoming catalysts in Q1 2015.
    Uribe A
    Nat Rev Drug Discov; 2015 Jan; 14(1):9. PubMed ID: 25503330
    [No Abstract]   [Full Text] [Related]  

  • 4. Business barriers slowing the pace of cancer immunotherapy research and development.
    Tuma RS
    J Natl Cancer Inst; 2007 Nov; 99(21):1570-3. PubMed ID: 17971521
    [No Abstract]   [Full Text] [Related]  

  • 5. [Effects and costs of adjuvant chemotherapy for operable lymph node positive breast cancer with HER2/neu overexpression].
    Bult P; Tjan-Heijnen VC; van Krieken H
    Ned Tijdschr Geneeskd; 2006 Jul; 150(26):1481; author reply 1481-3. PubMed ID: 16875274
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost utility of sequential adjuvant trastuzumab for HER2/Neu-positive breast cancer.
    Reed SD; Schulman KA
    Value Health; 2009; 12(5):637-40. PubMed ID: 19473336
    [No Abstract]   [Full Text] [Related]  

  • 7. Cancer charity demands extension of drug fund despite criticisms it is unfair.
    Limb M
    BMJ; 2014 Oct; 349():g6507. PubMed ID: 25354675
    [No Abstract]   [Full Text] [Related]  

  • 8. Market spiral pricing of cancer drugs.
    Light DW; Kantarjian H
    Cancer; 2013 Nov; 119(22):3900-2. PubMed ID: 24002792
    [No Abstract]   [Full Text] [Related]  

  • 9. Where to with HER2?
    Sledge GW
    Clin Breast Cancer; 2010 Feb; 10(1):18. PubMed ID: 20133253
    [No Abstract]   [Full Text] [Related]  

  • 10. Individualization of neoadjuvant therapy for breast cancer according to molecular tumor characteristics.
    Hennessy BT; Gonzalez-Angulo AM; Hortobagyi GN
    Nat Clin Pract Oncol; 2005 Dec; 2(12):598-9. PubMed ID: 16341096
    [No Abstract]   [Full Text] [Related]  

  • 11. Targeted therapy for human epidermal growth factor receptor 2-positive breast cancer: can there be too many active drugs?
    Chandarlapaty S; Modi S
    J Clin Oncol; 2011 Aug; 29(23):3111-3. PubMed ID: 21730267
    [No Abstract]   [Full Text] [Related]  

  • 12. HER2 status and benefit from adjuvant trastuzumab in breast cancer.
    Paik S; Kim C; Wolmark N
    N Engl J Med; 2008 Mar; 358(13):1409-11. PubMed ID: 18367751
    [No Abstract]   [Full Text] [Related]  

  • 13. Pfizer makes breast cancer drug free while NICE decides its future.
    Kmietowicz Z
    BMJ; 2017 May; 357():j2225. PubMed ID: 28483771
    [No Abstract]   [Full Text] [Related]  

  • 14. [Position statement of the (Hungarian) College of Oncology and Radiotherapy regarding the financing of Tyverb (lapatinib) based on individual discretionary compassionate care].
    Pikó B;
    Magy Onkol; 2009 Mar; 53(1):77-9. PubMed ID: 19318330
    [No Abstract]   [Full Text] [Related]  

  • 15. Associations Between Industry Sponsorship and Results of Cost-effectiveness Analyses of Drugs Used in Breast Cancer Treatment.
    Lane JD; Friedberg MW; Bennett CL
    JAMA Oncol; 2016 Feb; 2(2):274-6. PubMed ID: 26658959
    [No Abstract]   [Full Text] [Related]  

  • 16. Trastuzumab: new indication. Adjuvant breast cancer treatment for a minority.
    Prescrire Int; 2007 Jun; 16(89):106. PubMed ID: 17582927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Herceptin monotherapy in HER2(+) recurrent breast carcinoma].
    Eidtmann H
    Onkologie; 2002 Dec; 25 Suppl 5():14-5. PubMed ID: 23573613
    [No Abstract]   [Full Text] [Related]  

  • 18. [HER-2/neu oncogene in the selection of treatment for breast cancer and as a target of immunotherapy].
    Isola J; Järvinen T; Tanner M; Holli K
    Duodecim; 2000; 116(15):1538-46. PubMed ID: 12001473
    [No Abstract]   [Full Text] [Related]  

  • 19. Optimism after much pessimism: what next?
    Milstein C; Waldmann H
    Curr Opin Immunol; 1999 Oct; 11(5):589-91. PubMed ID: 10508713
    [No Abstract]   [Full Text] [Related]  

  • 20. [Hepatic toxicity in HER-2(+) breast cancer patient under treatment with capecitabine and lapatinib].
    Romero Carreño E; Marcos Rodríguez JA; Santana Martínez S; de la Cruz Merino L
    Farm Hosp; 2016 Mar; 40(2):134-6. PubMed ID: 26980172
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.